Literature DB >> 28192876

Determination of 16 serum angiogenic factors in stage I non-small cell lung cancer using a bead-based multiplex immunoassay.

Agnieszka Klupczynska1, Paweł Dereziński1, Jan Matysiak1, Wojciech Dyszkiewicz2, Mariusz Kasprzyk2, Zenon J Kokot3.   

Abstract

The aim of the study was to identify significant abnormalities in angiogenic factor profiles occurring at early-stage non-small cell lung cancer (NSCLC). Contrary to the previous studies, our research included patients with only stage I NSCLC, which allowed for estimating the utility of circulating angiogenic factors in early NSCLC detection. The investigation was performed in serum samples collected from individuals with untreated NSCLC (n=41) and a matched control group of healthy individuals (n=61). All patients had histopathologically-confirmed stage IA or IB NSCLC. Serum concentrations of 16 angiogenesis markers comprising growth factors, receptors, cytokines, chemokines and hormones, were measured using a bead-based multiplex immunoassay. Among the determined proteins, osteopontin, platelet-derived growth factor-AB and -BB (PDGF-AB/BB) and hepatocyte growth factor (HGF) demonstrated the largest increase in concentration in NSCLC patients as compared with the non-cancer group. ROC curve analysis confirmed their high discriminatory abilities in detection of early NSCLC (AUC=0.809, 95%CI 0.725-0.881). Serum levels of the studied angiogenic factors differed slightly between patients with lung adenocarcinoma and squamous cell carcinoma. The study demonstrated that osteopontin, PDGF-AB/BB, and HGF might add up to the methods used in NSCLC diagnosis. Future research should address the question about their specificity and performance in early NSCLC detection in a combination with various putative lung cancer markers.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Biomarkers; Non-small cell lung cancer; Osteopontin

Mesh:

Substances:

Year:  2017        PMID: 28192876     DOI: 10.1016/j.biopha.2017.01.141

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  3 in total

1.  SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

Authors:  Siwen Hu-Lieskovan; Srabani Bhaumik; Kavita Dhodapkar; Jean-Charles J B Grivel; Sumati Gupta; Brent A Hanks; Sylvia Janetzki; Thomas O Kleen; Yoshinobu Koguchi; Amanda W Lund; Cristina Maccalli; Yolanda D Mahnke; Ruslan D Novosiadly; Senthamil R Selvan; Tasha Sims; Yingdong Zhao; Holden T Maecker
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

2.  Prognostic value of plasminogen activator inhibitor-1 in biomarker exploration using multiplex immunoassay in patients with metastatic renal cell carcinoma treated with axitinib.

Authors:  Naoko Honma; Takamitsu Inoue; Norihiko Tsuchiya; Atsushi Koizumi; Ryohei Yamamoto; Taketoshi Nara; Sohei Kanda; Mingguo Huang; Kazuyuki Numakura; Mitsuru Saito; Shintaro Narita; Shigeru Satoh; Tomonori Habuchi
Journal:  Health Sci Rep       Date:  2020-10-15

3.  High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers.

Authors:  Alessandra Rossi; Minna Voigtlaender; Hans Klose; Hartmut Schlüter; Gerhard Schön; Sonja Loges; Moreno Paolini; Carsten Bokemeyer; Martin Reck; Giulio Tarro; Mascha Binder
Journal:  J Oncol       Date:  2019-08-22       Impact factor: 4.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.